Table 1 Molecular radiotherapies and possibilities for dosimetric treatment planning identified in the report
Radiopharmaceutical | Procedure | Compounds used for pre-treatment imaging | Post-treatment imaging or measurement methods |
|---|---|---|---|
131I NaI | Benign thyroid disease | 131I NaI 124I NaI 123I NaI | Thyroid probe. Gamma cameraa or SPECT/CT. |
131I NaI | Differentiated thyroid cancer (DTC) with ablative intent and in the case of recurrent disease | 131I NaI 124I NaI 123I NaI | Gamma camera or SPECT/CT. Whole-body probes, blood sampling |
131I mIBG | Neuroblastoma in children and young adults | 131I mIBG 124I mIBG 123I mIBG | Whole-body probe for bone marrow estimation. Gamma camera or SPECT/CT |
131I mIBG | Neuroendocrine tumors in adults | 131I mIBG 124I mIBG 123I mIBG | Gamma camera or SPECT/CT |
177Lu DOTATATE | Neuroendocrine tumors | Radiolabelled somatostatin analogs | Gamma camera or SPECT/CT |
90Y somatostatin analogs | Adult neuroendocrine disease | Analogs, as 86Y–DOTATOC 111In-DOTATATE | Bremsstrahlung gamma camera or SPECT/CT. PET/CT. |
89SrCl2, 153Sm-EDTMP, 186Re-HEDP, and 188Re-HEDP | Bone pain palliation | 99mTc-MDP for 153Sm-EDTMP | Gamma camera or SPECT/CT for 153Sm-EDTMP, 186Re-HEDP and 188Re-HEDP |
223Ra dichloride | Bone metastases from castration-resistant prostate cancer | 99mTc-MDP | Planar gamma camera imaging |
177Lu PSMA ligands | Metastatic castration-resistant prostate cancer | Analog PET ligands | SPECT/CT |
90Y microspheres | Liver metastases or primary tumors | 99mTc-albumin macro aggregate | Bremsstrahlung SPECT/CT. PET/CT. |
90Y-ibritumomab tiuxetan | Non-Hodgkin’s lymphoma | 111In-ibritumomab tiuxetan | Bremsstrahlung gamma camera or SPECT/CT. PET/CT. |
90Y, 32P, and 186Re colloid, 169Er citrate | Radiosynovectomy | 99mTc MDP/HDP/HEDP and/or 99mTc-HIG | Planar Gamma camera imaging, # dicentric chromosomes |